[Federal Register Volume 75, Number 84 (Monday, May 3, 2010)]
[Notices]
[Pages 23272-23274]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-10264]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Retroviral Vectors for Selective Reversible Immortalization of
Stimulus-responding Primary Cells
Description of Invention: Researchers at the National Cancer
Institute-Frederick, NIH, have developed a novel set of retroviral
vectors and producer cell lines useful for selective reversible
immortalization of primary cells (i.e. lymphocytes) that respond to a
stimulus, such as a viral antigen (e.g.
[[Page 23273]]
HIV toxoids), a tumor antigen, or a growth factor.
Derived from the murine leukemia virus (MuLV), these retroviral
vectors will only infect dividing cells. Therefore, only primary cells
activated by the stimulus will be infected and immortalized, thereby
creating an ``antigen-specific trap.''
The primary cells to be immortalized can be in targeted tissue or
in stimulated ex vivo culture. The transduced cells can be expanded to
large numbers without differentiating, and returned to the primary cell
stage by removal of the introduced genes using a vector excision
strategy.
Applications
Isolation/replication of normally short-lived primary
cells that respond to a stimulus.
Immortalization of antigen-specific T cells for vaccine
development or adoptive transfer immunotherapy.
Production of primary cell lines for large-scale
production of cell-secreted factors, cytokines, and other molecules.
Advantages
System acts as an anti-senescence treatment: Cells that
are normally short-lived can be kept in culture for years.
Vectors with different markers are available to identify
transduced cells and for cell selection.
Excision allows for gene/marker removal.
The MuLV-based system only infects dividing (e.g.
activated) cells
Inventors: Eugene V. Barsov and David E. Ott (NCI).
Relevant Publications
1. E Barsov et al. Capture of antigen-specific T lymphocytes from human
blood by selective immortalization to establish long-term T-cell lines
maintaining primary cell characteristics. Immunol Lett. 2006 May
15;105(1):26-37. [PubMed: 16442639]
2. H Andersen et al. Transduction with human telomerase reverse
transcriptase immortalizes a rhesus macaque CD8+ T cell clone with
maintenance of surface marker phenotype and function. AIDS Res Hum
Retroviruses 2007 Mar;23(3):456-465. [PubMed: 17411379]
Patent Status: HHS Reference No. E-140-2010/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: Available for biological materials licensing
only.
Licensing Contact: Patrick P. McCue, PhD; 301-435-5560;
[email protected].
Collaborative Research Opportunity: The Center for Cancer Research,
AIDS and Cancer Virus Program, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. Please contact
John Hewes, PhD at 301-435-3131 or [email protected]. for more
information.
A Method of Measuring Ultraviolet A (UVA) Protection in Sunscreen
Products
Description of Invention: There are different types of ultraviolet
(UV) rays in sunlight. UVB radiation causes redness (erythema) or
sunburn. While UVA radiation, which absorbs deep into the skin, causes
more long-term effects such as wrinkles, skin aging and skin cancer.
Effective sunscreens are expected to block both UVA and UVB
radiation. The Sun Protection Factor (SPF) label found on all over-the-
counter sunscreen products is a better measure for UVB protection than
UVA protection. Currently, there is no standard in vivo test to
determine the amount of UVA protection in sunscreen products, despite
the fact that many products are advertised as effectively blocking both
UVA and UVB radiation.
This invention describes sets of genes useful for measuring UVA
exposure in human skin and assessing sunscreen products for their
ability to block UVA radiation.
Application: A test for measuring UVA protection provided by
sunscreens.
Development Status: Early stage.
Market: According to a report by the Global Industry Analysts,
Inc., the sun care market is projected to reach $5.6 billion by the
year 2015.
Inventors: Atsushi Terunuma and Jonathan C. Vogel (NCI).
Related Publication: In preparation.
Patent Status: U.S. Provisional Application No. 61/309,179 filed 01
Mar 2010 (HHS Reference No. E-097-2010/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Charlene Sydnor, PhD; 301-435-4689;
[email protected].
Collaborative Research Opportunity: The Center for Cancer Research,
Dermatology Branch, is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize this technology. Please contact John Hewes,
PhD at 301-435-3131 or [email protected] for more information.
Laser Scanning Microscopy for Three Dimensional Motion Tracking for
Volumetric Data
Description of Invention: The technology offered for licensing and
for further development is in the field of volumetric tissue scanning
microscopy. More specifically, the invention provides for a device,
system and methods that can acquire and analyze volumetric data from a
high-speed laser-scanning microscope and compute motion of the sample
under the microscope in three dimensions. This computed motion is used
to adjust position of the sample in real time to maintain field of view
and relative location. This motion compensation scheme can be used to
collect micron-scale information over time, which can be important in a
number of research or medical device applications.
Applications
Biomedical research involving in vivo microscopy.
Real time tracking of cells or cellular structures.
Tracking tissue during various physiological perturbations
and observation of dynamic physiological processes. Physiological
perturbations include metabolic substrates, drug delivery and anoxia.
Potential applications in molecular diagnostic imaging.
Potential applications in medical procedures such as
biopsy and microsurgery where information has to be collected from a
specific microscope location over a period of time.
Advantages
Improved analytical capabilities for biological processes.
Improved capabilities of accurately examining and studying
physiological perturbations.
Potential improvement in medical procedures such as
biopsy.
May readily be adaptable to commercial microscopes.
Development Status: The invention is fully developed. Further work
needs to be done in the following areas:
Adaptation to different types of microscopes.
Further demonstration of utility of in-vivo imaging.
Inventors: James L. Schroeder (NHLBI) et al.
Related Publication: Schroeder JL, Luger-Hamer M, Pursley R, Pohida
T, Chefd'Hotel C, Kellman P, Balaban RS. Short communication:
Subcellular motion compensation for minimally invasive microscopy, in
vivo: evidence for oxygen gradients in resting muscle.
[[Page 23274]]
Circ Res. 2010 Apr 2;106(6):1129-1133. [PubMed: 20167928].
Patent Status: U.S. Provisional Application No. 61/245,586 filed 24
Sep 2009 (HHS Reference No. E-290-2009/0-US-01).
Licensing Status: Available for licensing.
Licensing Contacts: Uri Reichman, PhD, MBA; 301-435-4616;
[email protected], or Michael Shmilovich, Esq.; 301-435-5019;
[email protected].
Collaborative Research Opportunity: The National Heart, Lung, and
Blood Institute, Laboratory of Cardiac Energetics, is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
automatic 3D volumetric motion tracking systems for use during in vivo
microscopy. Please contact Denise Crooks, PhD at 301-435-0103 or
[email protected] for more information.
Dated: April 26, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-10264 Filed 4-30-10; 8:45 am]
BILLING CODE 4140-01-P